PDF Cover

Advanced Cancer Diagnostics Market

The market for Advanced Cancer Diagnostics was estimated at $63.5 billion in 2025; it is anticipated to increase to $99.4 billion by 2030, with projections indicating growth to around $156 billion by 2035.

Report ID:DS1806024
Author:Debadatta Patel - Senior Consultant
Published Date:
Datatree
Life Science
Other Healthcare
Advanced Cancer Diagnostics
Share
Report Summary
Market Data
Methodology
Table of Contents

Global Advanced Cancer Diagnostics Market Outlook

Revenue, 2025

$63.5B

Forecast, 2035

$155B

CAGR, 2026 - 2035

9.4%

The Advanced Cancer Diagnostics industry revenue is expected to be around $63.5 billion in 2026 and expected to showcase growth with 9.4% CAGR between 2026 and 2035. Advanced cancer diagnostic techniques are highly significant in the fight against cancer worldwide, due to the emphasis by oncologists on treatment which is both effective and cost efficient and early diagnosis. Growing cancer incidence rates, the increasing adoption of precision oncology and the growing field of personalised cancer care, are all major drivers of the expansion of the cancer diagnostics market. The trend is being driven by developments in several fields including liquid biopsy platforms, genomic profiling, AI powered imaging and molecular diagnostics. This has resulted in deeper integration of these technologies into cancer care.

A comprehensive range of molecular diagnostics tests and tools, including molecular and genetic diagnostics, tests for cancer biomarkers, next generation DNA sequencing methods and companion diagnostic tools, plus imaging and digital pathology are available through Advanced Cancer Diagnostics. Together breast and lung cancer account for approximately 57.4% of the market demand, with further growth anticipated in the region's of colorectal, prostate and leukaemic cancers. In these latter conditions, there is an increasing use of both advanced cancer diagnostic techniques and analysis of the genetic makeup of the tumour. The molecular and genomic diagnostics sector dominated the market in 2025 with $19.29 billion revenue. This was due to the fact that clinicians were favouring the use of multi gene panels for comprehensive profiling of tumours and the monitoring of patients through minimally invasive techniques. As a consequence of recent technological advancements, liquid biopsy is increasingly being used for the purpose of assessing treatment response and also for the surveillance of cancer recurrence. Moreover, interoperability of diagnostic information across different healthcare networks is set to improve, and decentralised testing is also becoming more prevalent. Advanced cancer diagnostics are likely to remain central to cancer treatment.

Advanced Cancer Diagnostics market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2025-2035
Advanced Cancer Diagnostics Market Outlook

Market Key Insights

  • By 2035 the global market for advanced cancer diagnostics will have reached $156 billion from $63.5 billion in 2025. The sector has achieved a compound annual growth rate of 9.4 %; this is a result of the increasing need for early disease detection, for treatment tailored to the individual and for monitoring the progress of patients.

  • Market leaders shaping the competitive landscape of this industry are Thermo Fisher Scientific, Roche Diagnostics and Illumina Inc.

  • The US and France will see the most significant growth in the field of advanced cancer diagnostics over the forecast period. This growth will occur at an estimated compound annual rate of 6.9 9.9%.

  • Markets which are developing, such as those in India, Brazil and South Africa, are expected to experience the most growth, at a rate of between 9% and 11.8% compound annually.

  • The expected shift towards personalised medicine is likely to contribute around $8 billion to the cancer diagnostics market growth by 2030.

  • The market for advanced cancer diagnostics will grow by nearly $92.4 billion by the year 2035, as industry leaders seek out new lung cancer and colorectal cancer applications.

  • The Advanced Cancer Diagnostics industry is anticipated to nearly quadruple by 2035 due to the widespread use of newer imaging technology. This significant growth should occur between 2025 and 2035.

advanced cancer diagnostics market size with pie charts of major and emerging country share, CAGR, trends for 2025 and 2032
Advanced Cancer Diagnostics - Country Share Analysis

Opportunities in the Advanced Cancer Diagnostics

Integrating companion diagnostic tools, next generation sequencing and liquid biopsy in standard American cancer care is also enabling precision oncology. Molecular diagnostics, by which $19 billion is generated globally in 2025 and $31 billion in 2030, are at present the sector which is growing at the quickest rate. There is significant potential in partnerships between academic research institutions, pharmaceutical companies and diagnostic laboratories for biomarker discovery. These partnerships can lead to a diverse range of cancer diagnostic products and robust clinical tools to aid targeted therapies.

Growth Opportunities in North America and Asia-Pacific

Advanced cancer diagnostics in North America is a sector that is supported by well established insurance reimbursement, a strong commitment to precision cancer treatment, plus an extensive network of cancer detection services. Mammography has been widely adopted in this region because of the large number of breast cancer cases and it is complemented by the increasing demand for molecular screening tools which can be used to help decide which cancer treatments will be most effective. A high level of competition is seen in the in vitro diagnostics and oncology imaging industries, as well as within the field of genomic laboratories. This is driving innovation in the fields of liquid biopsy, genetic analysis and AI assisted treatment monitoring and risk assessment. These opportunities revolve around the use of integrated diagnostic pathways which link breast cancer diagnostics with imaging technologies and genetic information, and also involve increased point of care testing at clinics in order to screen women who are in lower socio economic groups. Investments should be made in scalable and interoperable systems which tie in pathology, radiology and genetic information. This would allow hospitals and laboratories to differentiate through cancer services, tailored to value based care systems.
The region of the Asia Pacific is witnessing a rapid adoption of Advanced Cancer Diagnostics. This growth is largely due to an expansion in healthcare systems and an increase in oncology capacity. Lung cancer has become the most significant application in this region. This is primarily due to the high incidence of lung cancer which is often linked to smoking prevalence and urban air pollution, along with the fact that it is usually diagnosed at a late stage. The factors driving the market for these tests are increasing healthcare costs, a national screening programme and a rapid adoption of targeted treatments which rely on accurate diagnostic techniques at the molecular level and companion diagnostics. The latter applies particularly to EGFR and ALK biomarkers. In the competitive market, a mix of international companies and small regional producers supply low cost diagnostic tests, imaging equipment and liquid biopsy systems, where the pricing of the products, the region's they cover with their services and how the technology is used are the key distinguishing factors. There are significant opportunities in the implementation of cost effective and high capacity genomic analysis for lung cancer, in the use of AI for cancer diagnosis to give imaging services priority and the roll out of modular cancer diagnostic systems. By forging alliances with local public health programs, oncology networks and diagnostic laboratories, service providers will be able to establish themselves in these rapidly expanding cancer diagnostic and screening markets.

Market Dynamics and Supply Chain

01

Driver: Technological Advancements in Imaging Techniques, and Government and Private Sector Investments

Cutting edge advancements in imaging such as PET scans, MRI scans and CT scans are also propelling the growth of the sophisticated cancer diagnosis sector. The use of invasive and high quality imaging technologies allows for early and accurate detection leading to improved treatment outcomes and recovery rates for individuals, with cancerous ailments. Substantial funding from government entities and private companies has also sparked enthusiasm in the field of cancer research. This support has also led to the creation of cutting edge instruments that are also driving forward the market for advanced cancer diagnostics. Moreover these efforts have also played a role, in detecting cancer at an early stage and improving patient results significantly.
The increasing occurrence ofs of cancer worldwide highlights the need for more advanced methods of diagnosis. The rise in cancer cases can also be attributed to factors such as population growth and aging demographics alongside lifestyle changes and genetic influences. This trend is also driving the growth of the market, for solutions.
02

Restraint: High Associated Costs

A significant obstacle that could hinder the expansion of Advanced Cancer Diagnostics is the nature of these tests. This issue often impacts the affordability and access to diagnostic procedures in regions, with limited or underfunded healthcare infrastructure. Addressin this challenge may involve making pricing choices and potentially sacrificing immediate profits for manufacturers to encourage future growth and market reach.
03

Opportunity: Population-based early cancer screening initiatives across China and India using advanced imaging-based diagnostics and Digital histopathology and cytology services for community oncology clinics in underserved Latin American markets

Across China and India, there is increasing population screening for a number of diseases. As a result there is growing demand for early cancer diagnosis techniques. The imaging diagnostics market worldwide is predicted to grow from $17.32 billion in 2025 to $26.65 billion in 2030. This sector will expand quickly due to an increase in the use of low dose modalities and AI powered imaging systems in secondary and tertiary healthcare facilities. A large untapped market exists in cloud enabled, image analysis solutions as well as low cost point of care testing bundles for public health organisations that deal in high volumes, these can improve healthcare access for people in urban and rural region's who have been underserved previously.
Across Latin America many cancer clinics in low income communities suffer from a severe shortage of highly trained specialist pathologists, this makes diagnosing advanced cancers very difficult. Digital diagnostics in cytology and histopathology are expected to witness a sizeable growth, rising from $15.1 billion in 2025 to $22.9 billion by 2030. The market for diagnostic services is likely to expand in region's including cloud based image management, telepathology, and cytology, all of which can provide quicker diagnoses and support treatments at hospitals and public labs.
04

Challenge: Lack of Awareness and Education

Another notable limitation is the knowledge and understanding regarding the significance and need for Advanced Cancer Diagnostics Tests. Cancer is frequently identified in stages because of the absence of early detection methods or neglect of the advantages of early identification.

Supply Chain Landscape

1

Molecular Diagnostics Inputs

Thermo Fisher ScientificRoche DiagnosticsIllumina Inc
2

Advanced Cancer Diagnostics

Roche DiagnosticsSiemens HealthineersGE HealthCare
3

Genomic Sequencing Systems

Illumina Inc.Thermo Fisher ScientificGE HealthCare
4

Precision Oncology Users

HospitalsOncology ClinicsDiagnostic Laboratories
Advanced Cancer Diagnostics - Supply Chain

Use Cases of Advanced Cancer Diagnostics in Early Detection & Personalized Treatment Planning

Early Detection : The field of Advanced Cancer Diagnostics has transformed the way we detects of cancer early on by using sophisticated technologies like ML algorithms and deep genomic sequencing techniques to pinpoint DNA and RNA mutations at an initial phase and thereby enabling prompt treatment initiation advantageously ahead of time. Notable companies such, as OncoDNA and Freenome excel in this domain.
Personalized Treatment Planning : Utilizing these tools proves to be extremely beneficial in personalizing cancer therapies by accurately profiling the patients tumor characteristics and enabling oncologists to customize treatments as per individuals genetic composition. Insight Genetics and Guardant Health are players, in this groundbreaking field.
Monitoring Patient Progress : Advanced Cancer Diagnostics also allow for the monitoring of progress in real time during treatment by tracking dynamic shifts in tumor genetics to assess treatment efficacy and determine the need for adjustments to avoid ineffective treatments unnecessarily exposed to patients. This approach is effectively carried out by players such, as Foundation Medicine and NeoGenomics Labs.

Recent Developments

In the evolving landscape of Advanced Cancer Diagnostics today we see a surge in advancements and a rise in cancer cases that emphasize the shift towards tailored treatment options for this life threatening illness. Cutting edge diagnostic tests like Liquid Biopsies and AI powered tools along, with Next generation Sequencing are revolutionizing the field by providing accurate and less invasive alternatives compared to conventional approaches.

December 2024 : Illumina Inc introduced a method, for genomic sequencing to improve the early detection of variouss of cancer.
October 2024 : Bio Radiant Labs unveiled a cutting edge molecular diagnostics device that incorporates AI algorithms to enhance the precision of identifying cancer cells.
August 2024 : Roche Diagnostics created a liquid biopsy test that offers faster outcomes when analyzing cancer mutations.

Impact of Industry Transitions on the Advanced Cancer Diagnostics Market

As a core segment of the Other Healthcare industry, the Advanced Cancer Diagnostics market develops in line with broader industry shifts. Over recent years, transitions such as Shift Towards Personalized Medicine and Rise of Liquid Biopsy have redefined priorities across the Other Healthcare sector, influencing how the Advanced Cancer Diagnostics market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.
01

Shift Towards Personalized Medicine

Personalised medicine is the driver of a shift towards a more targeted approach in the advanced cancer diagnostics sector, where a patients individual characteristics are used to provide a diagnosis. This shift is expected to increase market revenue by $8 billion by 2030. As precision cancer medicine and the genetic testing of tumours becomes a more normal part of healthcare, companies are focusing their efforts on creating diagnostic tools that are capable of effectively categorising the risk posed by cancer, of assisting in the choice of the best treatment and of spotting any cancer remaining after treatment which can cause a patient to ill again. The shift to precision medicine is driving investment in technologies including companion diagnostics and liquid biopsy. This has led to earlier treatments and more suitable treatment options being selected across alls of cancer. Companies that adapt their products and services to match clinically validated workflows which make use of biomarkers will take advantage of a large share of the market. This is due to health care providers and insurance companies offering higher payments for diagnostic tools which prove that they reduce costs and improve outcomes for cancer patients.
02

Rise of Liquid Biopsy

The liquid biopsy trend for diagnosing cancer, signifies a departure from traditional biopsy methods. These are often invasive and associated with possible side effects.